Compare Cassava Sciences Inc (FLNA) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $66.99 (market cap $7.24B). The key difference: Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is far larger — about 183.8× Cassava Sciences Inc's market cap, and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 0 Days on average.
| FLNA | VIST | |
|---|---|---|
Market Cap | $39.40M | $7.24B |
Volume | 759,018 | 752,518 |
Sector | Health | Energy |
52-Week High | $4.64 | $79.25 |
52-Week Low | $0.68 | $35.02 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | -$43.28M | $10.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
